GW Pharmaceuticals PLC- (GWPH) Short Interest Update

GW Pharmaceuticals PLC- (NASDAQ:GWPH) saw a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 1,289,057 shares, a decline of 41.3% from the January 12th total of 2,195,299 shares. Based on an average daily volume of 427,328 shares, the days-to-cover ratio is currently 3.0 days. Approximately 5.1% of the company’s shares are sold short.

Several equities analysts have weighed in on the stock. Leerink Swann boosted their target price on shares of GW Pharmaceuticals PLC- from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Tuesday, February 6th. Zacks Investment Research lowered shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. BidaskClub lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Bank of America decreased their target price on shares of GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating on the stock in a report on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $192.00 target price (down from $208.00) on shares of GW Pharmaceuticals PLC- in a report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $146.38.

Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of GW Pharmaceuticals PLC- by 0.4% in the 2nd quarter. Royal Bank of Canada now owns 4,240 shares of the biopharmaceutical company’s stock worth $424,000 after acquiring an additional 18 shares during the last quarter. Advisor Group Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 145 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 8.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 162 shares during the last quarter. Eqis Capital Management Inc. lifted its holdings in shares of GW Pharmaceuticals PLC- by 12.6% in the 4th quarter. Eqis Capital Management Inc. now owns 3,791 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 424 shares during the last quarter. Finally, Aperio Group LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 12.0% in the 4th quarter. Aperio Group LLC now owns 5,325 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 569 shares during the last quarter. Hedge funds and other institutional investors own 74.49% of the company’s stock.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $126.06 on Monday. The company has a quick ratio of 7.47, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a fifty-two week low of $92.65 and a fifty-two week high of $143.37. The company has a market cap of $3,200.00, a P/E ratio of -14.26 and a beta of 2.50.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. The company had revenue of $7.73 million during the quarter, compared to analyst estimates of $2.18 million. research analysts anticipate that GW Pharmaceuticals PLC- will post -9.18 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/gw-pharmaceuticals-plc-gwph-short-interest-update.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply